Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676663 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00676663 is a Phase 2 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 130 participants.
The verdict
NCT00676663, a Phase 2 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
Interventions
- DRUG Placebo
- DRUG exemestane
- DRUG entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-06-13 |
| Est. Completion | 2012-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676663
The ClinicalTrials.gov registry entry for NCT00676663 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00676663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676663 about?
NCT00676663 is a clinical study titled "Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer". The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
What is the current status of trial NCT00676663?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-06-13. Estimated completion is 2012-11-26.
What interventions are being tested in trial NCT00676663?
The interventions under investigation include: Placebo (DRUG), exemestane (DRUG), entinostat (DRUG).
Who is sponsoring clinical trial NCT00676663?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.